164 related articles for article (PubMed ID: 26916006)
41. Extracellular heat shock protein 90 plays a role in translocating chaperoned antigen from endosome to proteasome for generating antigenic peptide to be cross-presented by dendritic cells.
Oura J; Tamura Y; Kamiguchi K; Kutomi G; Sahara H; Torigoe T; Himi T; Sato N
Int Immunol; 2011 Apr; 23(4):223-37. PubMed ID: 21421737
[TBL] [Abstract][Full Text] [Related]
42. Targeting heat-shock-protein 90 (Hsp90) by natural products: geldanamycin, a show case in cancer therapy.
Franke J; Eichner S; Zeilinger C; Kirschning A
Nat Prod Rep; 2013 Oct; 30(10):1299-323. PubMed ID: 23934201
[TBL] [Abstract][Full Text] [Related]
43. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
Workman P
Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
[TBL] [Abstract][Full Text] [Related]
44. Small-molecule targeting of heat shock protein 90 chaperone function: rational identification of a new anticancer lead.
Meli M; Pennati M; Curto M; Daidone MG; Plescia J; Toba S; Altieri DC; Zaffaroni N; Colombo G
J Med Chem; 2006 Dec; 49(26):7721-30. PubMed ID: 17181154
[TBL] [Abstract][Full Text] [Related]
45. HSP90: a rising star on the horizon of anticancer targets.
Dai C; Whitesell L
Future Oncol; 2005 Aug; 1(4):529-40. PubMed ID: 16556029
[TBL] [Abstract][Full Text] [Related]
46. Lead generation of heat shock protein 90 inhibitors by a combination of fragment-based approach, virtual screening, and structure-based drug design.
Miura T; Fukami TA; Hasegawa K; Ono N; Suda A; Shindo H; Yoon DO; Kim SJ; Na YJ; Aoki Y; Shimma N; Tsukuda T; Shiratori Y
Bioorg Med Chem Lett; 2011 Oct; 21(19):5778-83. PubMed ID: 21875802
[TBL] [Abstract][Full Text] [Related]
47. HSP90 Inhibition Enhances Cancer Immunotherapy by Modulating the Surface Expression of Multiple Immune Checkpoint Proteins.
Zavareh RB; Spangenberg SH; Woods A; Martínez-Peña F; Lairson LL
Cell Chem Biol; 2021 Feb; 28(2):158-168.e5. PubMed ID: 33113406
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of the mitochondrial Hsp90 chaperone network: a novel, efficient treatment strategy for cancer?
Siegelin MD
Cancer Lett; 2013 Jun; 333(2):133-46. PubMed ID: 23376257
[TBL] [Abstract][Full Text] [Related]
49. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
[TBL] [Abstract][Full Text] [Related]
50. Efficient induction of antitumor T cell immunity by exosomes derived from heat-shocked lymphoma cells.
Chen W; Wang J; Shao C; Liu S; Yu Y; Wang Q; Cao X
Eur J Immunol; 2006 Jun; 36(6):1598-607. PubMed ID: 16708399
[TBL] [Abstract][Full Text] [Related]
51. Hsp90-downregulation influences the heat-shock response, innate immune response and onset of oocyte development in nematodes.
Eckl J; Sima S; Marcus K; Lindemann C; Richter K
PLoS One; 2017; 12(10):e0186386. PubMed ID: 29078207
[TBL] [Abstract][Full Text] [Related]
52. Targeting the Extracellular HSP90 Co-Chaperone Morgana Inhibits Cancer Cell Migration and Promotes Anticancer Immunity.
Seclì L; Avalle L; Poggio P; Fragale G; Cannata C; Conti L; Iannucci A; Carrà G; Rubinetto C; Miniscalco B; Hirsch E; Poli V; Morotti A; De Andrea M; Turco E; Cavallo F; Fusella F; Brancaccio M
Cancer Res; 2021 Sep; 81(18):4794-4807. PubMed ID: 34193441
[TBL] [Abstract][Full Text] [Related]
53. Functions of heat shock proteins in pathways of the innate and adaptive immune system.
Binder RJ
J Immunol; 2014 Dec; 193(12):5765-71. PubMed ID: 25480955
[TBL] [Abstract][Full Text] [Related]
54. The Unmysterious Roles of HSP90: Ovarian Pathology and Autoantibodies.
Pires ES
Adv Anat Embryol Cell Biol; 2017; 222():29-44. PubMed ID: 28389749
[TBL] [Abstract][Full Text] [Related]
55. Detection and Analysis of Extracellular Hsp90 (eHsp90).
Cortes S; Baker-Williams AJ; Mollapour M; Bourboulia D
Methods Mol Biol; 2018; 1709():321-329. PubMed ID: 29177669
[TBL] [Abstract][Full Text] [Related]
56. The Effect of Heat Shock Protein 90 Inhibitor on Pain in Cancer Patients: A Systematic Review and Meta-Analysis.
Miles VN; Patel RK; Smith AG; McCall RP; Wu J; Lei W
Medicina (Kaunas); 2020 Dec; 57(1):. PubMed ID: 33374669
[TBL] [Abstract][Full Text] [Related]
57. Inhibiting the molecular evolution of cancer through HSP90.
Martins AS; Davies FE; Workman P
Oncotarget; 2012 Oct; 3(10):1054-6. PubMed ID: 23175477
[No Abstract] [Full Text] [Related]
58. Extracellular Hsp90 (eHsp90) as the actual target in clinical trials: intentionally or unintentionally.
Li W; Tsen F; Sahu D; Bhatia A; Chen M; Multhoff G; Woodley DT
Int Rev Cell Mol Biol; 2013; 303():203-35. PubMed ID: 23445811
[TBL] [Abstract][Full Text] [Related]
59. A Fluorescent Hsp90 Probe Demonstrates the Unique Association between Extracellular Hsp90 and Malignancy in Vivo.
Crowe LB; Hughes PF; Alcorta DA; Osada T; Smith AP; Totzke J; Loiselle DR; Lutz ID; Gargesha M; Roy D; Roques J; Darr D; Lyerly HK; Spector NL; Haystead TAJ
ACS Chem Biol; 2017 Apr; 12(4):1047-1055. PubMed ID: 28103010
[TBL] [Abstract][Full Text] [Related]
60. HSP90 Mediates IFNγ-Induced Adaptive Resistance to Anti-PD-1 Immunotherapy.
Liu K; Huang J; Liu J; Li C; Kroemer G; Tang D; Kang R
Cancer Res; 2022 May; 82(10):2003-2018. PubMed ID: 35247909
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
